Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the FDA boxed warning topic areas (cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer) and correctly cites supporting label sections (Boxed Warning; 5.1, 5.2, 5.3; WHI/WHIMS references in 14.5/14.6 in the provided excerpts).
Category Scores
Accurate Statements
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER risk (boxed warning content).
BOXED WARNING section header includes these four risk categories; text includes cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer guidance.
Boxed Warning explicitly includes Endometrial Cancer, Cardiovascular Disorders, Probable Dementia, and Breast Cancer, including statements of increased risks and directives such as 'Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia' and the analogous 'estrogen plus progestogen' statement.
BOXED WARNING excerpts include endometrial cancer risk with unopposed estrogen, and both 'Do not use estrogen-alone...' and 'Do not use estrogen plus progestogen...' statements.
5.1 Cardiovascular Disorders: reports increased risks of PE, DVT, stroke and MI with estrogen plus progestin therapy; increased risks of stroke and DVT with estrogen-alone therapy; includes instruction to discontinue if these occur or are suspected.
Section 5.1 excerpt: increased risks listed and 'Immediately discontinue estrogen with or without progestogen therapy if any of these occur or is suspected.'
5.2 Malignant Neoplasms: states increased endometrial cancer risk with unopposed estrogen in women with a uterus; states adding a progestogen reduces endometrial hyperplasia risk; describes increased invasive breast cancer risk with CE plus MPA vs placebo.
Section 5.2 excerpts: unopposed estrogen endometrial cancer risk; adding progestogen reduces endometrial hyperplasia risk; increased invasive breast cancer with CE plus MPA vs placebo.
5.3 Probable Dementia: WHIMS data reporting increased risk of probable dementia for CE plus MPA vs placebo.
Section 5.3 excerpt: WHIMS probable dementia diagnosis counts and increased risk language for CE plus MPA vs placebo.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation is limited to whether the stated boxed warning risk categories and supporting content are accurately represented; no dosing or contraindication guidance was asserted beyond what is contained in the provided boxed warning excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement